Role of glycosphingolipids and therapeutic perspectives on Alzheimer's disease

Tatsuro Mutoh, Yoshio Hirabayashi, Takateru Mihara, Madoka Ueda, Hiroshi Koga, Akihiro Ueda, Takako Kokura, Hiroko Yamamoto

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.

Original languageEnglish
Pages (from-to)375-380
Number of pages6
JournalCNS and Neurological Disorders - Drug Targets
Volume5
Issue number4
DOIs
Publication statusPublished - 01-08-2006

Fingerprint

Glycosphingolipids
Presenilins
Alzheimer Disease
Nerve Growth Factors
Protein Transport
Neurodegenerative Diseases
Therapeutics
Lipids
Peptides
Proteins

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Pharmacology

Cite this

Mutoh, Tatsuro ; Hirabayashi, Yoshio ; Mihara, Takateru ; Ueda, Madoka ; Koga, Hiroshi ; Ueda, Akihiro ; Kokura, Takako ; Yamamoto, Hiroko. / Role of glycosphingolipids and therapeutic perspectives on Alzheimer's disease. In: CNS and Neurological Disorders - Drug Targets. 2006 ; Vol. 5, No. 4. pp. 375-380.
@article{d67a84af8482498eb86aa51c99274894,
title = "Role of glycosphingolipids and therapeutic perspectives on Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10{\%} of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.",
author = "Tatsuro Mutoh and Yoshio Hirabayashi and Takateru Mihara and Madoka Ueda and Hiroshi Koga and Akihiro Ueda and Takako Kokura and Hiroko Yamamoto",
year = "2006",
month = "8",
day = "1",
doi = "10.2174/187152706777950710",
language = "English",
volume = "5",
pages = "375--380",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

Mutoh, T, Hirabayashi, Y, Mihara, T, Ueda, M, Koga, H, Ueda, A, Kokura, T & Yamamoto, H 2006, 'Role of glycosphingolipids and therapeutic perspectives on Alzheimer's disease', CNS and Neurological Disorders - Drug Targets, vol. 5, no. 4, pp. 375-380. https://doi.org/10.2174/187152706777950710

Role of glycosphingolipids and therapeutic perspectives on Alzheimer's disease. / Mutoh, Tatsuro; Hirabayashi, Yoshio; Mihara, Takateru; Ueda, Madoka; Koga, Hiroshi; Ueda, Akihiro; Kokura, Takako; Yamamoto, Hiroko.

In: CNS and Neurological Disorders - Drug Targets, Vol. 5, No. 4, 01.08.2006, p. 375-380.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of glycosphingolipids and therapeutic perspectives on Alzheimer's disease

AU - Mutoh, Tatsuro

AU - Hirabayashi, Yoshio

AU - Mihara, Takateru

AU - Ueda, Madoka

AU - Koga, Hiroshi

AU - Ueda, Akihiro

AU - Kokura, Takako

AU - Yamamoto, Hiroko

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Alzheimer's disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.

AB - Alzheimer's disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.

UR - http://www.scopus.com/inward/record.url?scp=33746938256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746938256&partnerID=8YFLogxK

U2 - 10.2174/187152706777950710

DO - 10.2174/187152706777950710

M3 - Article

C2 - 16918389

AN - SCOPUS:33746938256

VL - 5

SP - 375

EP - 380

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 4

ER -